1
|
Boutros A, Carosio R, Campanella D, Spagnolo F, Banelli B, Morabito A, Pistillo M, Croce E, Cecchi F, Pronzato P, Queirolo P, Raposio E, Fontana V, Tanda E. The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors. Immunooncol Technol 2023; 20:100408. [PMID: 38192613 PMCID: PMC10772261 DOI: 10.1016/j.iotech.2023.100408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/10/2024]
Abstract
Background Despite having revolutionized the treatment paradigm for advanced melanoma, not all patients benefit from immune checkpoint inhibitor therapy. To date, there are no predictive biomarkers for response or the occurrence of immune-related adverse events (irAEs) to programmed cell death protein 1 (PD-1) inhibitors. Our aim was to investigate the predictive and prognostic role of single nucleotide variants (SNVs) of genes involved in the PD-1 axis. Methods We analysed, in metastatic melanoma patients treated with nivolumab or pembrolizumab, five PD-1 SNVs, namely PD1.3 G>A (rs11568821), PD1.5 C>T (rs2227981), PD1.6 G>A (rs10204525), PD1.7 T>C(rs7421861), PD1.10 C>G (rs5582977) and three programmed death-ligand 1 (PD-L1) SNVs: +8293 C>A (rs2890658), PD-L1 C>T (rs2297136) and PD-L1 G>C (rs4143815). Association of SNV genotypic frequencies with best overall response to PD-1 inhibitors and development of irAEs were estimated through a modified Poisson regression. A Cox regression modelling approach was applied to evaluate the SNV association with OS. Results A total of 125 patients with advanced melanoma were included in the analysis. A reduction in irAEs risk was observed in patients carrying the PD-L1 +8293 C/A genotype compared with those carrying the C/C genotype (risk ratio = 0.45; 95% CL 0.22-0.93; P = 0.031). A trend for a reduction in irAEs was also observed with the PD1.5 T allele (risk ratio = 0.70, 95% confidence limits 0.48-1.01 versus C allele). None of the SNVs was associated with response to therapy. Finally, a survival benefit was observed in patients harbouring the PD1.7 C/C genotype (hazard ratio = 0.37; 95% confidence limits 0.14-0.96; P = 0.028) in the homozygous model. Conclusions Our study showed that PD-1.5 and PD-L1 +8293 SNVs may play a role as a predictive biomarker of development of irAEs to PD-1 inhibitors. PD1.7 SNV may also be associated with a reduction of the risk of death, although further translational research is needed to confirm these results.
Collapse
Affiliation(s)
- A. Boutros
- Skin Cancer Unit, Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genoa
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa
| | - R. Carosio
- Tumor Epigenetics Unit, IRCCS Ospedale Policlinico San Martino, Genoa
| | - D. Campanella
- Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa
| | - F. Spagnolo
- Skin Cancer Unit, Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genoa
- Department of Surgical Sciences and Integrated Diagnostics (DISC), Plastic Surgery Division, University of Genova, Genoa
| | - B. Banelli
- Tumor Epigenetics Unit, IRCCS Ospedale Policlinico San Martino, Genoa
| | - A. Morabito
- Tumor Epigenetics Unit, IRCCS Ospedale Policlinico San Martino, Genoa
| | - M.P. Pistillo
- Tumor Epigenetics Unit, IRCCS Ospedale Policlinico San Martino, Genoa
| | - E. Croce
- Skin Cancer Unit, Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genoa
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa
| | - F. Cecchi
- Skin Cancer Unit, Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genoa
| | - P. Pronzato
- Skin Cancer Unit, Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genoa
| | - P. Queirolo
- Division of Melanoma Sarcoma and Rare Tumors, IRCCS European Institute of Oncology, Milan, Italy
| | - E. Raposio
- Department of Surgical Sciences and Integrated Diagnostics (DISC), Plastic Surgery Division, University of Genova, Genoa
| | - V. Fontana
- Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa
| | - E.T. Tanda
- Skin Cancer Unit, Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genoa
| |
Collapse
|
2
|
Boutros A, Carosio R, Campanella D, Spagnolo F, Banelli B, Morabito A, Pistillo M, Croce E, Cecchi F, Pronzato P, Queirolo P, Fontana V, Tanda E. 24P The predictive and prognostic role of single nucleotide gene variants in PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
3
|
Vigani A, Salvi S, Varesano S, Boccardo S, Ferro P, Canessa P, Franceschini M, Dessanti P, Ravetti J, Fedeli F, Pistillo M, Roncella S. Evaluation of MET gene status in malignant mesothelioma by fluorescent in situ hybridization. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Bigley AB, Rezvani K, Shah N, Sekine T, Balneger N, Pistillo M, Agha N, Kunz H, O'Connor DP, Bollard CM, Simpson RJ. Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans. Clin Exp Immunol 2016; 185:239-51. [PMID: 26940026 PMCID: PMC4955006 DOI: 10.1111/cei.12785] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2016] [Revised: 02/27/2016] [Accepted: 02/29/2016] [Indexed: 12/22/2022] Open
Abstract
Cytomegalovirus (CMV) infection markedly expands NKG2C+/NKG2A- NK cells, which are potent killers of infected cells expressing human leucocyte antigen (HLA)-E. As HLA-E is also over-expressed in several haematological malignancies and CMV has been linked to a reduced risk of leukaemic relapse, we determined the impact of latent CMV infection on NK cell cytotoxicity against four tumour target cell lines with varying levels of HLA-E expression. NK cell cytotoxicity against K562 (leukaemia origin) and U266 (multiple myeloma origin) target cells was strikingly greater in healthy CMV-seropositive donors than seronegative donors and was associated strongly with target cell HLA-E and NK cell NKG2C expression. NK cell cytotoxicity against HLA-E transfected lymphoma target cells (221.AEH) was ∼threefold higher with CMV, while NK cell cytotoxicity against non-transfected 721.221 cells was identical between the CMV groups. NK cell degranulation (CD107a(+) ) and interferon (IFN)-γ production to 221.AEH cells was localized almost exclusively to the NKG2C subset, and antibody blocking of NKG2C completely eliminated the effect of CMV on NK cell cytotoxicity against 221.AEH cells. Moreover, 221.AEH feeder cells and interleukin (IL)-15 were found to expand NKG2C(+) /NKG2A(-) NK cells preferentially from CMV-seronegative donors and increase NK cell cytotoxicity against HLA-E(+) tumour cell lines. We conclude that latent CMV infection enhances NK cell cytotoxicity through accumulation of NKG2C(+) NK cells, which may be beneficial in preventing the initiation and progression of haematological malignancies characterized by high HLA-E expression.
Collapse
Affiliation(s)
- A. B. Bigley
- Laboratory of Integrated Physiology, Department of Health and Human PerformanceUniversity of HoustonHoustonTXUSA
| | - K. Rezvani
- Department of Stem Cell Transplantation, Division of Cancer MedicineThe University of Texas MD Anderson Cancer CenterHoustonTXUSA
| | - N. Shah
- Department of Stem Cell Transplantation, Division of Cancer MedicineThe University of Texas MD Anderson Cancer CenterHoustonTXUSA
| | - T. Sekine
- Department of Stem Cell Transplantation, Division of Cancer MedicineThe University of Texas MD Anderson Cancer CenterHoustonTXUSA
| | - N. Balneger
- Laboratory of Integrated Physiology, Department of Health and Human PerformanceUniversity of HoustonHoustonTXUSA
| | - M. Pistillo
- Laboratory of Integrated Physiology, Department of Health and Human PerformanceUniversity of HoustonHoustonTXUSA
| | - N. Agha
- Laboratory of Integrated Physiology, Department of Health and Human PerformanceUniversity of HoustonHoustonTXUSA
| | - H. Kunz
- Laboratory of Integrated Physiology, Department of Health and Human PerformanceUniversity of HoustonHoustonTXUSA
| | - D. P. O'Connor
- Laboratory of Integrated Physiology, Department of Health and Human PerformanceUniversity of HoustonHoustonTXUSA
| | - C. M. Bollard
- Program for Cell Enhancement and Technologies for Immunotherapy, Sheikh Zayed Institute for Pediatric Surgical Innovation and Center for Cancer and Immunology ResearchChildren's National Health SystemWashingtonDCUSA
| | - R. J. Simpson
- Laboratory of Integrated Physiology, Department of Health and Human PerformanceUniversity of HoustonHoustonTXUSA
| |
Collapse
|
5
|
Roncella S, Canessa P, Franceschini M, Manta C, Dessanti P, Vigani A, Fontana V, Fedeli F, Pistillo M, Ferro P. 711 Clinical Significance of Human Mammaglobin Expression in Pleural Effusion From Patients With Negative Thoracoscopy. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71407-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
6
|
Grossi F, Rijavec E, Barletta G, Genova C, Dal Bello M, Salvi S, Merlo D, Ratto G, Truini M, Pistillo M. 1446 POSTER Evaluation of CTL Antigen 4 (CTLA-4) Expression as Prognostic Factor in Non-small Cell Lung Cancer (NSCLC). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70939-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Simeone E, Gentilcore G, Esposito A, Curvietto M, De Rosa P, De Maio E, Pistillo M, Queirolo P, Mozzillo N, Ascierto P. 9322 POSTER Immunological and Biological Changes and Their Correlation With Clinical Response and Survival During Ipilimumab in Metastatic Melanoma Compassionate Use Program. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72531-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
8
|
Roncella S, Ferro P, Bacigalupo B, Pronzato P, Franceschini M, Pratticò L, Carletti A, Canessa P, Fontana V, Pistillo M, Fedeli F. Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusions. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Palmisano G, Tazzari P, Martelli A, Falà F, Fabbi M, Kato T, Lucarelli E, Polito L, Bolognesi A, Ricci F, Salvi S, Mantero S, Pistillo M. 183 Targeting CTLA-4 by its recombinant ligands CD80/CD86: Perspectives towards the development of a novel anti-tumor therapeutic approach. Radiother Oncol 2006. [DOI: 10.1016/s0167-8140(06)80661-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Urlacher A, Laforet M, Pistillo M, Tongio M. The role of a given epitope in cellular versus serological alloresponse. Hum Immunol 1994. [DOI: 10.1016/0198-8859(94)90159-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
11
|
Pistillo M, Tazzari P, Mazzoleni O, Ferrara G. Use of cytoflourimetry and cell-elisa to define HLA specificity of human monoclonal antibodies. Hum Immunol 1991. [DOI: 10.1016/0198-8859(91)90175-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
12
|
Ferrara G, Stefani E, Tincani A, Balestrieri G, Pistillo M, Tucci A, Mazzoleni O, Ceppellini R, Cattaneo R. Dissection of B cell immune responses in autoimmune diseases by the methodology of human MoABs production. Hum Immunol 1988. [DOI: 10.1016/0198-8859(88)90142-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Patanè AM, Pistillo M. [Antimicrobial action of benzoyl peroxide]. Ann Sclavo 1982; 24:513-22. [PMID: 6821331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|